News
Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...
2d
MedPage Today on MSNNew Bispecific T-Cell Engager Approved for Multiple MyelomaA B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...
21h
GlobalData on MSNRegeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myelomaRegeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of ...
While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...
The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...
1d
MedPage Today on MSNFor Your Myeloma Patients: Are You a Candidate for Autologous Stem Cell Transplant?Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...
Regeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...
The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...
Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...
Multiple myeloma, a treatable but incurable blood cancer, is rising sharply in India, especially among those over 60. Dr.
The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results